BTG1 expression in thyroid carcinoma: Diagnostic indicator and prognostic marker

Lu,Y. F.; Sun,G. G.; Liu,Q.; Yang,C. R.; Cheng,Y. J.

doi:10.3892/ijo.2014.2543

BTG1 expression in thyroid carcinoma: Diagnostic indicator and prognostic marker

Authors:
- Y. F. Lu
- G. G. Sun
- Q. Liu
- C. R. Yang
- Y. J. Cheng
View Affiliations

Affiliations: Department of Endocrinology, Tangshan Workers Hospital, Tangshan 063000, P.R. China, Department of Chemoradiotherapy, Tangshan People's Hospital, Tangshan 063000, P.R. China, Department of Radiotherapy, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050017, P.R. China
Published online on: July 11, 2014 https://doi.org/10.3892/ijo.2014.2543
Pages: 1574-1582

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

We determined the expression and function of B cell translocation gene 1 (BTG1) in thyroid carcinoma. Thyroid samples were obtained from cancer lesions (n=83) and adjacent normal tissue (n=35) in thyroid cancer patients immediately after endoscopic biopsy. BTG1 expression was determined by immunohistochemistry and western blotting. The effect of BTG1 overexpression was examined in vitro utilizing the human thyroid cancer cell line FTC-133, stably transfected with a recombinant lentivirus (LeBTG1 cells) and compared to empty vector transfected controls (LeEmpty). BTG1 overexpression was verified by reverse transcription quantitative polymerase chain reaction (RT-qPCR) and western blotting. The expression of proteins involved in cell cycle regulation (cyclin D1), apoptosis (Bcl-2) and cell migration (MMP-9) in LeBTG1 cells was analyzed by western blotting. The effect of BTG1 overexpression on cell viability and proliferation was assessed by MTT assay in LeBTG1 and LeEmpty cells. Flow cytometric analyses were used to evaluate the effect of BTG1 expression on cell cycle distribution and apoptosis. The migration and invasion potential of LeBTG1 cells was examined by plating cells in Matrigel-coated chambers. BTG1 protein expression was significantly lower in thyroid cancer tissue biopsies compared to normal tissue as measured by immunohistochemistry (36.1 vs. 80.0% of tissues; P<0.05) and western blotting (0.251±0.021 vs. 0.651±0.065; P<0.05). Decreased expression of BTG1 was significantly correlated with thyroid cancer lymph node metastasis, clinical stage and pathological differentiation (P<0.05), as well as with reduced overall 10‑year survival rates compared to patients with higher expression levels (30.2 vs. 66.7%; P<0.05). In vitro analyses revealed that LeBTG1 cells had a reduced survival fraction compared to control LeEmpty cells, with higher rates of apoptosis (11.6±2.1 vs. 2.1±0.4%; P<0.05). The proportion of LeBTG1 cells in G0/G1 stage and S phase was also significantly different from LeEmpty cells (81.8±6.3 and 10.2±1.0%, vs. 62.4±4.9 and 25.5±2.6%, respectively; P<0.05), and the migration and invasion of LeBTG1 cells was significantly impaired with respect to LeEmpty cells (72.0±8.0 and 55.0±7.0 vs. 113.0±16.0 and 89.0±9.0, respectively; P<0.05). These effects were accompanied by decreased protein expression of cyclin D1, Bcl-2 and MMP-9 in LeBTG1 cells (0.234±0.018, 0.209±0.021, 0.155±0.017, respectively) compared to control LeEmpty cells (0.551±0.065, 0.452±0.043, 0.609±0.072, respectively; P<0.05). Reduced BTG1 expression is associated with increased disease severity, suggesting it is a negative regulator of thyroid cancer and can serve as a prognostic indicator.

View Figures

View References

1	Agathocleous M and Harris WA: Metabolism in physiological cell proliferation and differentiation. Trends Cell Biol. 23:484–492. 2013. View Article : Google Scholar : PubMed/NCBI
2	Hofmockel G: Molecular genetic principles of tumor development and progression. Urologe A. 39:212–213. 2000.(In German).
3	Shibata D and Aaltonen LA: Genetic predisposition and somatic diversification in tumor development and progression. Adv Cancer Res. 80:83–114. 2001. View Article : Google Scholar
4	Lee EY and Muller WJ: Oncogenes and tumor suppressor genes. Cold Spring Harb Perspect Biol. 2:a0032362010.PubMed/NCBI
5	Okuyama T, Maehara Y, Kabashima A, Takahashi I, Kakeji Y and Sugimachi K: Combined evaluation of expressions of p53 and p21 proteins as prognostic factors for patients with gastric carcinoma. Oncology. 63:353–361. 2002. View Article : Google Scholar : PubMed/NCBI
6	Vadgama JV, Scuric Z, Chakrabarti R, Marzo E, Shen D and Wu Y: Insulin-like growth factor I differentially regulates the expression of HIRF1/hCAF1 and BTG1 genes in human MCF-7 breast cancer cells. Int J Mol Med. 18:129–139. 2006.PubMed/NCBI
7	Cortes U, Moyret-Lalle C, Falette N, Duriez C, Ghissassi FE, Barnas C, Morel AP, Hainaut P, Magaud JP and Puisieux A: BTG gene expression in the p53-dependent and -independent cellular response to DNA damage. Mol Carcinog. 27:57–64. 2000. View Article : Google Scholar : PubMed/NCBI
8	Winkler GS: The mammalian anti-proliferative BTG/Tob protein family. J Cell Physiol. 222:66–72. 2010. View Article : Google Scholar : PubMed/NCBI
9	Rouault JP, Rimokh R, Tessa C, Paranhos G, Ffrench M, Duret L, Garoccio M, Germain D, Samarut J and Magaud JP: BTG1, a member of a new family of antiproliferative genes. EMBO J. 11:1663–1670. 1992.PubMed/NCBI
10	Rouault JP, Falette N, Guéhenneux F, Guillot C, Rimokh R, Wang Q, Berthet C, Moyret-Lalle C, Savatier P, Pain B, Shaw P, Berger R, Samarut J, Magaud JP, Ozturk M, Samarut C and Puisieux A: Identification of BTG2, an antiproliferative p53-dependent component of the DNA damage cellular response pathway. Nat Genet. 14:482–486. 1996. View Article : Google Scholar : PubMed/NCBI
11	Matsuda S, Rouault J, Magaud J and Berthet C: In search of a function for the TIS21/PC3/BTG1/TOB family. FEBS Lett. 497:67–72. 2001. View Article : Google Scholar : PubMed/NCBI
12	Bozec A, Peyrade F and Milano G: Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives. Anticancer Agents Med Chem. 13:389–402. 2013.PubMed/NCBI
13	Suzuki K, Nakamura K, Kato K, Hamada H and Tsukamoto T: Exploration of target molecules for prostate cancer gene therapy. Prostate. 67:1163–1173. 2007. View Article : Google Scholar : PubMed/NCBI
14	Turashvili G, Bouchal J, Ehrmann J, Fridman E, Skarda J and Kolar Z: Novel immunohistochemical markers for the differentiation of lobular and ductal invasive breast carcinomas. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 151:59–64. 2007. View Article : Google Scholar : PubMed/NCBI
15	Ranganathan V and De PK: Western blot of proteins from Coomassie-stained polyacrylamide gels. Anal Biochem. 234:102–104. 1996. View Article : Google Scholar : PubMed/NCBI
16	van Meerloo J, Kaspers GJ and Cloos J: Cell sensitivity assays: the MTT assay. Methods Mol Biol. 731:237–245. 2011.PubMed/NCBI
17	Rasola A and Geuna M: A flow cytometry assay simultaneously detects independent apoptotic parameters. Cytometry. 45:151–157. 2001. View Article : Google Scholar : PubMed/NCBI
18	Kramer N, Walzl A, Unger C, Rosner M, Krupitza G, Hengstschläger M and Dolznig H: In vitro cell migration and invasion assays. Mutat Res. 752:10–24. 2013. View Article : Google Scholar
19	Richards RJ: Responsibility for statistical analyses. Endocr Pract. 9:3292003.PubMed/NCBI
20	Zhu R, Zou ST, Wan JM, Li W, Li XL and Zhu W: BTG1 inhibits breast cancer cell growth through induction of cell cycle arrest and apoptosis. Oncol Rep. 30:2137–2144. 2013.PubMed/NCBI
21	Manjili MH, Najarian K and Wang XY: Signatures of tumor-immune interactions as biomarkers for breast cancer prognosis. Future Oncol. 8:703–711. 2012. View Article : Google Scholar : PubMed/NCBI
22	Martinez-Outschoorn UE, Pavlides S, Sotgia F and Lisanti MP: Mitochondrial biogenesis drives tumor cell proliferation. Am J Pathol. 178:1949–1952. 2011. View Article : Google Scholar : PubMed/NCBI
23	Koff A, Cross F, Fisher A, Schumacher J, Leguellec K, Philippe M and Roberts JM: Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family. Cell. 66:1217–1228. 1991. View Article : Google Scholar : PubMed/NCBI
24	Tirone F: The gene PC3(TIS21/BTG2), prototype member of the PC3/BTG/TOB family: regulator in control of cell growth, differentiation, and DNA repair? J Cell Physiol. 187:155–165. 2001. View Article : Google Scholar : PubMed/NCBI
25	Nicholson DW and Thornberry NA: Apoptosis. Life and death decisions. Science. 299:214–215. 2003. View Article : Google Scholar : PubMed/NCBI
26	Corjay MH, Kearney MA, Munzer DA, Diamond SM and Stoltenborg JK: Antiproliferative gene BTG1 is highly expressed in apoptotic cells in macrophage-rich areas of advanced lesions in Watanabe heritable hyperlipidemic rabbit and human. Lab Invest. 78:847–858. 1998.
27	Lee H, Cha S, Lee MS, Cho GJ, Choi WS and Suk K: Role of antiproliferative B cell translocation gene-1 as an apoptotic sensitizer in activation-induced cell death of brain microglia. J Immunol. 171:5802–5811. 2003. View Article : Google Scholar : PubMed/NCBI
28	Nahta R, Yuan LX, Fiterman DJ, Zhang L, Symmans WF, Ueno NT and Esteva FJ: B cell translocation gene 1 contributes to antisense Bcl-2-mediated apoptosis in breast cancer cells. Mol Cancer Ther. 5:1593–1601. 2006. View Article : Google Scholar : PubMed/NCBI
29	Wiseman BS and Werb Z: Stromal effects on mammary gland development and breast cancer. Science. 296:1046–1049. 2002. View Article : Google Scholar : PubMed/NCBI
30	Alok C and Bharat B: Nuclear factor-kappa Band cancer: its role in prevention and therapy. Biochem Phamacol. 64:883–888. 2002. View Article : Google Scholar : PubMed/NCBI
31	Virós D, Camacho M, Zarraonandia I, García J, Quer M, Vila L and León X: Prognostic role of MMP-9 expression in head and neck carcinoma patients treated with radiotherapy orchemoradiotherapy. Oral Oncol. 49:322–325. 2013.PubMed/NCBI